Contact us
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...
Insights from our Founder's blog, relevant podcasts and a deeper dive with our scientific communications.
07 January 2025
In this episode of Twinning Strategy, Angiex CEO Paul Jaminet discusses the development of AGX101, a TM4SF1-directed antibody-drug conjugate (ADC) designed to target tumor cells and their blood supply.
31 October 2024
Watch Angiex CEO Dr. Paul Jaminet and founder Dr. Harold Dvorak, a leading authority on angiogenesis, present at a Force Family Office webinar. This engaging session offers an inside look at Angiex’s development of AGX101, a first-in-class TM4SF1-directed antibody-drug conjugate (ADC) designed to target both tumor cells and the blood vessels that feed them
20 September 2024
Join Angiex CEO Dr. Paul Jaminet as he presents at the MedInvest 2024 October Meeting, offering a comprehensive overview of AGX101, the company’s first-in-class TM4SF1-directed antibody-drug conjugate (ADC).
17 November 2024
Taking place November 17-20, 2024 in Boston, Massachusetts, will feature a poster presentation by Angiex, titled “AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial.”
07 May 2024
Angiex founder publishes paper describing the TM4SF1 intracellular transport pathway utilized by AGX101
Angiex is an ambitious startup looking for the highest quality partners. If you can help, please contact us...